New targeted drug hopes to shrink Hard-to-Treat liver tumors
NCT ID NCT06600321
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This early-phase study tests an experimental drug called ALN-BCAT, alone or with an immunotherapy (pembrolizumab), in people with advanced liver cancer that has spread. The drug targets a specific genetic change (WNT pathway mutation) found in some liver cancers. The main goals are to check safety and find the best dose, and later to see if the drug shrinks tumors. About 158 adults whose cancer has not responded to prior treatment are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGPhoenix, Arizona, 85054, United States
-
Clinical Trial Site
RECRUITINGLa Jolla, California, 92037, United States
-
Clinical Trial Site
RECRUITINGLos Angeles, California, 90033, United States
-
Clinical Trial Site
RECRUITINGJacksonville, Florida, 32224, United States
-
Clinical Trial Site
RECRUITINGAtlanta, Georgia, 30322, United States
-
Clinical Trial Site
RECRUITINGChicago, Illinois, 60637, United States
-
Clinical Trial Site
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Clinical Trial Site
RECRUITINGRochester, Minnesota, 55905, United States
-
Clinical Trial Site
RECRUITINGNew York, New York, 10029, United States
-
Clinical Trial Site
RECRUITINGNew York, New York, 10032, United States
-
Clinical Trial Site
RECRUITINGCleveland, Ohio, 44106, United States
-
Clinical Trial Site
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
Clinical Trial Site
RECRUITINGDallas, Texas, 75390, United States
-
Clinical Trial Site
RECRUITINGHouston, Texas, 77030, United States
-
Clinical Trial Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Clinical Trial Site
RECRUITINGRichmond, Virginia, 23298, United States
-
Clinical Trial Site
RECRUITINGMilan, 20132, Italy
-
Clinical Trial Site
RECRUITINGRozzano, 20089, Italy
-
Clinical Trial Site
RECRUITINGVerona, 37134, Italy
-
Clinical Trial Site
RECRUITINGBusan, 49241, South Korea
-
Clinical Trial Site
RECRUITINGSeongnam, 13496, South Korea
-
Clinical Trial Site
RECRUITINGSeongnam, 13620, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.